PRME Revenue Misses by 73%
Prime Medicine ( NASDAQ:PRME ) , a genetic medicine innovator developing next-generation gene editing therapies, released its second quarter 2025 earnings on August 7, 2025. The company reported GAAP revenue of $1.1 million, substantially below analyst estimates of $4.18 million and driven solely ...
Prime Medicine, Inc. ( PRME ) Reports Q2 Loss, Lags Revenue Estimates
Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of -13.89% and -59.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Prime Medicine, Inc. ( Nasdaq: PRME ) , a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of ...
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - Prime Medicine ( NASDAQ:PRME )
CAMBRIDGE, Mass., Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Prime Medicine, Inc.
Align Technology Posts Downbeat Earnings, Joins Confluent,FormFactor And Other Big Stocks Moving Lower In Thursday Pre-Market Session - Anheuser-Busch InBev ( NYSE:BUD ) , Align Technology ( NASDAQ:ALGN )
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.4% on Thursday. Shares of Align Technology, Inc. ALGN fell sharply in pre-market trading after the company missed second-quarter earnings estimates and issued soft third-quarter guidance.
Why Meta Platforms Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Alignment Healthcare ( NASDAQ:ALHC ) , Align Technology ( NASDAQ:ALGN )
Shares of Meta Platforms, Inc. META rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and issued third-quarter sales guidance above estimates.
Prime Medicine Announces Pricing of Public Offering
CAMBRIDGE, Mass., July 30, 2025 ( GLOBE NEWSWIRE ) -- Prime Medicine, Inc. ( Nasdaq: PRME ) , a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 38,000,000 shares of ...
Prime Medicine, Inc. ( PRME ) Now Trades Above Golden Cross: Time to Buy?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech ...
Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday - AbCellera Biologics ( NASDAQ:ABCL ) , Absci ( NASDAQ:ABSI )
U.S. stocks were higher, with the Dow Jones index gaining around 100 points on Monday. Shares of Galaxy Digital GLXY rose sharply during Monday's session after the company announced it has partnered with K Wave Media to accelerate Bitcoin treasury strategies and have access to greater ...
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis
-- Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis ( CF ) -- -- Prime Medicine to receive up to $24 million in additional funding from the Cystic Fibrosis Foundation ...
KalVista Pharmaceuticals, Cogent Biosciences, WNS And Other Big Stocks Moving Higher On Monday - Amber International ( NASDAQ:AMBR ) , Baidu ( NASDAQ:BIDU )
U.S. stocks were lower, with the Dow Jones index falling over 100 points on Monday. Shares of KalVista Pharmaceuticals, Inc. KALV rose sharply during Monday's session after the company announced it won FDA approval for EKTERLY. The U.S.
Hut 8, Greenbrier And Other Big Stocks Moving Higher On Tuesday - Critical Metals ( NASDAQ:CRML ) , Blue Gold ( NASDAQ:BGL )
U.S. stocks were mixed, with the Dow Jones index falling over 100 points on Wednesday. Shares of Hut 8 Corp. HUT rose sharply during Wednesday's session after announcing a key infrastructure win in Ontario.
Prime Medicine to Participate in Upcoming Investor Conferences - Prime Medicine ( NASDAQ:PRME )
CAMBRIDGE, Mass., May 29, 2025 ( GLOBE NEWSWIRE ) -- Prime Medicine, Inc. PRME, a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences:
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
BMRN and NVAX are in the spotlight this week following announcement agreement and regulatory update.
This MongoDB Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - ATI ( NYSE:ATI ) , MongoDB ( NASDAQ:MDB )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Keybanc analyst Philip Gibbs downgraded the rating for ATI Inc. ATI from Overweight to Sector ...
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively.
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition - Prime Medicine ( NASDAQ:PRME )
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively.
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease - Prime Medicine ( NASDAQ:PRME )
-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative --
Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease
-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative ...
Prime Medicine, Inc. ( PRME ) Reports Q1 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of -25% and 68.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Vanda Pharmaceuticals ( VNDA ) Reports Q1 Loss, Tops Revenue Estimates
Vanda (VNDA) delivered earnings and revenue surprises of 9.09% and 6.47%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Twist Bioscience ( TWST ) Reports Q2 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) delivered earnings and revenue surprises of -17.86% and 0.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Cathie Wood's Crypto Shuffle: Pours $5.2 Million Into Newly Listed Solana Staking Fund, Dumps Bitcoin ETF And Buys Robinhood Dip - Grayscale Bitcoin Mini Trust ( BTC ) Common units of fractional undivided beneficial interest ( ARCA:BTC )
On Wednesday, Cathie Wood-led Ark Invest made significant trades, notably acquiring shares in Robinhood Markets Inc. HOOD, ARK 21Shares Bitcoin ETF ARKB, and 3iQ Solana Staking ETF. Ark Invest's flagship fund, ARK Innovation ETF ARKK, purchased 60,266 shares of Robinhood Markets Inc. on Wednesday.
Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics - ARK Genomic Revolution ETF ( BATS:ARKG ) , ARK Innovation ETF ( BATS:ARKK )
On Friday, April 11, 2025, Cathie Wood-led Ark Invest executed notable trades, shedding shares in UiPath Inc. PATH, Prime Medicine Inc. PRME, and Repare Therapeutics Inc. RPTX. Ark Invest's ARK Innovation ETF ARKK fund sold 4,256 shares of UiPath Inc.
Cathie Wood's Tuesday Bet: Ark Loads Up On More Robinhood Stock Amid Platform Expansion - Robinhood Markets ( NASDAQ:HOOD ) , ARK Innovation ETF ( BATS:ARKK )
On Tuesday, Cathie Wood-led Ark Invest made notable trades, including a significant purchase of Robinhood Markets Inc. HOOD. This move follows recent strategic investments by Ark in Robinhood, highlighting its growing interest in the financial services platform.
Why Prime Medicine Stock Was Climbing Higher This Week
News of a fresh investigational program was putting some zip into the shares of gene-editing company Prime Medicine ( NASDAQ: PRME ) across recent trading sessions. According to data compiled by S&P Global Market Intelligence, in reaction, bullish investors were propelling the company's stock ...
Why Prime Medicine Stock Is Soaring Today
Shares of Prime Medicine ( NASDAQ: PRME ) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m. ET and was up as much as 17% earlier in the day. The move up comes as the S&P 500 and Nasdaq Composite gained 0.4% and 0.7%, respectively.The clinical-stage biotech ...
Prime Medicine Unveils Program for the Treatment of Alpha-1 Antitrypsin Deficiency ( AATD )
-- Prime Editing has potential to be best-in-class approach for AATD -- -- Previously undisclosed program now emerging from within liver platform. leverages proprietary, universal liver ...
Cathie Wood's Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta - ARK Fintech Innovation ETF ( ARCA:ARKF ) , ARK Genomic Revolution ETF ( BATS:ARKG )
On Friday, Mar. 14, 2025, the Cathie Wood-led Ark Invest made significant trades involving GitLab Inc GTLB, Intellia Therapeutics Inc NTLA, Prime Medicine Inc PRME, UiPath Inc PATH, Ibotta Inc IBTA, Roblox Corp RBLX, Repare Therapeutics Inc RPTX, and CareDx Inc CDNA.
Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference - Prime Medicine ( NASDAQ:PRME )
CAMBRIDGE, Mass. , Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Prime Medicine, Inc.
12 High-Growth Stocks That Could Deliver Parabolic Returns
These 12 innovative companies could deliver exponential returns over the next quarter century.
Why I Keep Buying These 14 Incredible Growth Stocks
This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging industries.
PRME Stock Rises 11.8% on Collaboration With Bristol Myers
Prime Medicine collaborates with Bristol Myers Squibb for the development of T-cell therapies. Shares gain.
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
Changes are afoot at the company, and investors welcomed them.
Dow Dips 300 Points; Emcore Shares Spike Higher - Carnival ( NYSE:CCL )
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 300 points during on Monday. The Dow traded down 0.71% to 42,012.42 while the NASDAQ fell 0.52% to 18,026.03. The S&P 500 also fell, dropping, 0.45% to 5,712.53. Communication services shares fell by just ...
Crude Oil Moves Higher; Prime Medicine Shares Spike Higher - Prime Medicine ( NASDAQ:PRME )
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 200 points during on Monday. The Dow traded down 0.55% to 42,079.06 while the NASDAQ rose 0.14% to 18,144.66. The S&P 500 also fell, dropping, 0.14% to 5,730.18. Consumer staples shares jumped by 0.3% on ...
Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday - Prime Medicine ( NASDAQ:PRME )
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Monday. Shares of Prime Medicine, Inc. PRME rose sharply during Monday's session after the company announced a strategic research collaboration and license agreement with Bristol Myers Squibb to develop reagents for ...
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline - Bristol-Myers Squibb ( NYSE:BMY ) , Prime Medicine ( NASDAQ:PRME )
On Monday, Prime Medicine Inc. PRME announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co BMY to develop reagents for the next generation of ex vivo T-cell therapies.
Prime Medicine Unveils Strategically Focused Pipeline
-- Prioritizing Set of High Value Programs in Core Areas of Focus. Modularity of Prime Editing Platform Expected to Allow Prime Medicine to Generate Follow-on Candidates Rapidly and Efficiently -- -- Initial Clinical Data from Phase 1/2 Trial in CGD Expected in 2025 While Advancing Wilson's ...
2 Growth Stocks That Could Make You Richer
Discover two cutting-edge growth stocks that could revolutionize medicine and space exploration.
Prime Medicine ( PRME ) Stock: Buy or Sell Before Q2 Earnings?
While Prime Medicine's (PRME) pipeline progress is encouraging, the precarious cash position is worrisome. We advise a wait-and-watch approach before Q2 results.
Prime Medicine ( PRME ) Gains 16.4% in 3 Months: Buy Now or Wait?
While Prime Medicine (PRME) exhibits potential with its encouraging pipeline progress, the current cash position warrants caution. We advise a wait-and-watch approach at current levels.
Prime Medicine ( NYSE:PRME ) Upgraded to "Sell" by StockNews.com
StockNews.com upgraded shares of Prime Medicine ( NYSE:PRME - Free Report ) to a sell rating in a research report sent to investors on Wednesday morning. Several other brokerages also recently commented on PRME. HC Wainwright started coverage on shares of Prime Medicine in a report on Monday, ...
Prime Medicine ( NYSE:PRME ) Stock Rating Upgraded by StockNews.com
StockNews.com upgraded shares of Prime Medicine ( NYSE:PRME - Free Report ) to a sell rating in a report released on Wednesday. PRME has been the topic of a number of other reports. Wedbush restated an outperform rating and set a $12.00 price target on shares of Prime Medicine in a research ...
Prime Medicine ( NYSE:PRME ) Upgraded to "Sell" by StockNews.com
StockNews.com upgraded shares of Prime Medicine ( NYSE:PRME - Free Report ) to a sell rating in a report published on Tuesday. A number of other research analysts also recently issued reports on the stock. Chardan Capital assumed coverage on shares of Prime Medicine in a research report on ...
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.
Wall Street Analysts Believe Prime Medicine, Inc. ( PRME ) Could Rally 120.95%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 121% in Prime Medicine, Inc. (PRME). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion Portfolio
Alphabet may have strong insight into both company's industries.
Prime Medicine ( NYSE:PRME ) Upgraded to "Sell" by StockNews.com
StockNews.com upgraded shares of Prime Medicine ( NYSE:PRME - Free Report ) to a sell rating in a research note released on Tuesday. PRME has been the subject of a number of other reports. TD Cowen started coverage on shares of Prime Medicine in a report on Monday, April 8th.
